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INTRODUCTION
The remarkable success of medicine and public health over the 
past century has made it possible for elderly people to live longer than 
ever before. At present, people over 65 years account for 13% of World 
population,  which  will  swell  to  about  20%  by  2030,  as  the  ‘baby 
boomers’ age. Thus most physicians will spend a significant portion of 
their professional life dealing with health care of older adults (1).
As per WHO and National Policy for Older Persons, the age used 
to define Geriatric persons in India is 60 years. Life expectancy in India 
is  62.8  years  in  males  and  64  years  in  females.  (2)  In  India,  the 
expectation of life at birth has increased from about 33 years in 1941-51 
to over 60 years in 1991-2001. During past 20 years the life expectancy 
has increased roughly half a year per annum (3). 
The elderly population in India is the second largest in the world, 
next only to China. This population which was 77 million according to 
2001 census (7.5% of total population) is projected to increase to 137 
million in 2021. Their annual growth is higher (3%) when compared to 
growth  of  entire  population  (1.9%).  Trends  show  that  by  2050,  the 
elderly population of India will surpass the population of children below 
14 years. Thus in India also, the elderly population is on an increase, as 
in other regions of the globe. This population is more likely to present 
with chronic diseases and atypical manifestations of diseases. COPD is 
one of the chronic diseases found in this population.
COPD is  currently  the fourth leading cause of  death (4,  5,  8). 
COPD is a major cause of disability and death in most countries and 
contribute significantly to escalating health care costs (6). In a recent 
estimate  of  Disability  Adjusted  Life  Years  (DALYs)  lost  due  to  a 
chronic disease, COPD ranked ninth in the world (7). It is predicted that 
in 2020, COPD will be the third leading cause of death in the world and 
fifth leading cause of lost DALYs worldwide(8). So, it is necessary to 
concentrate  more  on  a  disease  which  is  not  only  prevalent  but  also 
increasing in prevalence year by year.                                 
COPD is  caused by smoking in  80-90% of cases(6).  The only 
known measure found to decrease the incidence of COPD and decrease 
its severity is smoking cessation (9).
Tobacco is responsible for half of all cancers in men and 25% of 
all  cancers  amongst  women  (10).  15%  of  smokers  develop  COPD. 
Quitting smoking by 50% of adults would reduce the mortality amongst 
smokers by tobacco to 33% by 2020(11).
It has been found that smoking is related to depression (12, 13). 
Studies show that genes for smoking and depression are closely related 
and hence cause doubling of depression amongst smokers. 
          Depression affects 10-12% of elderly attending primary care as 
per  Current  Geriatrics  Diagnosis  and  Treatment,  2004  edition.  The 
incidence of depression is much higher in Indian population compared 
to western data.
          The occurrence of depression in COPD patients increases the 
morbidity and mortality  in the latter.  Indeed studies have shown that 
depression plays a larger role in determining a patient’s quality of life 
than the severity of COPD(4). More alarming is the fact that <30% of 
health care providers recognize depression. Depression compounds the 
negative symptoms of COPD leading to longer hospital stays and higher 
mortality rates. So, diagnosis and treatment of depression is a must in all 
COPD patients (4).
Smoking is associated with both depression (12, 13) and COPD. 
Smoking, more than adds to the amount of depression in COPD patients. 
Paradoxically, studies show that nicotine has anti-depressant  effect  in 
short term but adds to depression in long term. People who quit smoking 
are more prone to depression (14) over the next 6 months and so, they 
cannot leave smoking. So, a vicious cycle results. 
So, this study was undertaken, to find out whether smoking per se 
is related to depression and if so whether it adds to depression in people 
with COPD.Since patients with COPD are nearly always smokers this 
study also tends to find out whether they are much more depressed than 
non-smoking controls. This is to stress that all COPD patients require 
screening for depression and if present should be appropriately treated.
Review 
of
Literature 
REVIEW OF LITERATURE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Definition
COPD is a disease state characterized by airflow limitation that is 
not fully reversible. The airflow limitation is usually both progressive 
and associated with an abnormal inflammatory response of the lungs to 
noxious particles or gases.(15)
A diagnosis of COPD should be considered in any patient who 
has symptoms of cough, sputum production, or dyspnea, and/or a history 
of exposure to risk factors for the disease. The diagnosis is confirmed by 
spirometry.  The  presence  of  a  post  bronchodilator  FEV1/FVC <70% 
confirms the presence of airflow limitation that is not fully reversible. 
Where  spirometry  is  unavailable,  the  diagnosis  of  COPD should  be 
made using all  available tools.  Clinical  symptoms and signs,  such as 
abnormal shortness of breath and increased forced expiratory time, can 
be  used  to  make  the  diagnosis.  A low peak flow is  consistent  With 
COPD, but has poor specificity since it  can be caused by other lung 
diseases  and  by  poor  performance.  In  the  interest  of  improving  the 
diagnosis of COPD, every effort should be made to provide access to 
standardized spirometry.  Chronic  cough and sputum production often 
precede the development of airflow limitation by many years; but not all 
individuals with cough and sputum production go on to develop COPD 
(15).
Classification of Severity
For educational reasons, a simple classification of disease severity 
into four stages is recommended. The management of COPD is largely 
symptom driven, and there is only an imperfect relationship between the 
degree of airflow limitation and the presence of symptoms. The staging, 
therefore,  is  a  pragmatic  approach aimed  at  practical  implementation 
and should only be regarded as an educational tool, and a very general 
indication of the approach to management. All FEV1 values refer to post 
bronchodilator FEV1.
Stage 0 : At  Risk  -  Characterized  by  chronic  cough  and 
sputum production. Lung function, as measured by 
spirometry, is still normal.
Stage I : Mild  COPD-  Characterized  by  mild  airflow 
limitation  (FEV1 /FVC1 <  70%  but  FEV1  > 80% 
predicted)  and usually,  but  not  always,  by  chronic 
cough  and  sputum  production.  At  this  stage,  the 
individual may not even be aware that his or her lung 
function is abnormal.
Stage II : Moderate  COPD  -  Characterized  by  worsening 
airflow  limitation  (50%  < FEV1  <80%  predicted) 
and  usually  the  progression  of  symptoms,  with 
shortness of breath typically developing on exertion. 
This  is  the  stage  at  which  patients  typically  seek 
medical  attention  because  of  dyspnea  or  an 
exacerbation of their disease.
Stage III : Severe COPD - characterized by further worsening 
of airflow limitation (30% < FEV1 <50% predicted), 
increased  shortness  of  breath,  and  repeated 
exacerbations  which  have  an  impact  on  patients’ 
quality of life.
Stage IV : Very  Severe  COPD  -  Characterized  by  severe 
airflow  limitation  (FEV1 <30%  predicted).  At  this 
stage,  quality  of  life  is  appreciably  impaired  and 
exacerbations may be life-threatening (15).
Poorly  reversible  airflow  limitation  associated  with 
bronchiectasis,  cystic fibrosis,  tuberculosis,  or  asthma is not  included 
except  in  so  far  as  these  conditions  overlap  with  COPD.  In  many 
developing  countries  both  pulmonary  tuberculosis  and  COPD  are 
common. Therefore, in all subjects with symptoms of COPD, a possible 
diagnosis of tuberculosis should be considered especially in areas where 
this  disease  is  known  to  be  prevalent.  In  countries  in  which  the 
prevalence of tuberculosis is greatly diminished, the possible diagnosis 
of this disease is sometimes overlooked.
Pathogenesis
COPD is characterized by chronic inflammation throughout the 
airways,  parenchyma,  and  pulmonary  vasculature.  Macrophages,  T 
lymphocytes  (predominately  CD8+),  and  neutrophils  are  increased  in 
various parts of the lung (15).
In addition to inflammation,  two other processes thought to be 
important in the pathogenesis of COPD are an imbalance of proteases 
and anti-proteases in the lung, and oxidative stress.
Inflammation  of  the  lungs  is  caused  by  exposure  to  inhaled 
noxious particles and gases. Cigarette smoke can induce inflammation 
and directly damage the lungs.
Pathology
Pathological  changes  characteristic  of  COPD  are  found  in  the 
central airways,  peripheral airways,  lung parenchyma,  and pulmonary 
vasculature.
In  the  central  airways  -the  trachea,  bronchi,  and  bronchioles 
greater than 2-4 mm in internal diameter - inflammatory cells infiltrate 
the surface epithelium. Enlarged mucus secreting glands and an increase 
in the number of goblet cells are associated with mucus hyper secretion. 
In the peripheral airways -small bronchi and bronchioles that have an 
internal  diameter  of  less  than  2  mm  -chronic  inflammation  leads  to 
repeated  cycles  of  injury  and  repair  of  the  airway  wall.  The  repair 
process  results  in  a  structural  remodeling  of  the  airway  wall,  with 
increasing collagen content and scar tissue formation that narrows the 
lumen and produces fixed airways obstruction.
Destruction of the lung parenchyma in COPD patients typically 
occurs  as  centrilobular  emphysema.  This  involves  dilatation  and 
destruction  of  the  respiratory  bronchioles.  These  lesions  occur  more 
frequently in the upper lung regions in milder cases, but in advanced 
disease they may appear diffusely throughout the entire lung and also 
involve destruction of the pulmonary capillary bed (15).
Pathophysiology
Pathological  changes  in  the  lungs  lead  to  corresponding 
physiological  changes  characteristic  of  the  disease,  including  mucus 
hyper  secretion,  ciliary  dysfunction,  airflow  limitation,  pulmonary 
hyperinflation,  gas  exchange  abnormalities,  pulmonary  hypertension, 
and cor pulmonale. They usually develop in this order over the course of 
the disease.
Mucus  hyper  secretion  and  ciliary  dysfunction  lead  to  chronic 
cough and sputum production. These symptoms can be present for many 
years before other symptoms or physiological abnormalities develop.
Expiratory airflow limitation, best measured by spirometry, is the 
hallmark physiological change of COPD and the key to the diagnosis of 
the  disease.  It  is  primarily  due  to  fixed  airways  obstruction  and  the 
consequent  increase  in  airways  resistance.  Destruction  of  alveolar 
attachments, which inhibits the ability of the small airways to maintain 
patency, plays a smaller role (15).
Epidemiology
In  the  Global  Burden  of  Disease  Study  conducted  under  the 
auspices of the WHO and the World Bank, the worldwide prevalence of 
COPD in 1990 was estimated to be 9.34/1,000 in men and 7.33/1,000 in 
women.
The limited data that are available indicate that morbidity due to 
COPD increases with age and is greater in men than women.
COPD is currently the fourth leading cause of death in the world, 
and further increases in the prevalence and mortality of the disease can 
be predicted in the coming decades (15).
Risk factors
Risk  factors  for  COPD  include  both  host  factors  and 
environmental  exposures,  and  the  disease  usually  arises  from  an 
interaction between these two types of factors. The host factor that is 
best documented is a rare hereditary deficiency of alpha-1 antitrypsin. 
Other genes involved in the pathogenesis of COPD have not yet been 
identified. The major environmental factors are tobacco smoke; heavy 
exposure to occupational dusts and chemicals (vapors, irritants, fumes); 
and indoor/outdoor air pollution (15).
The ATS Definition of COPD
Internationally  accepted  opinion,  including  the  1995  ATS 
statement, has defined COPD as a disease state characterized by chronic 
airflow limitation due to chronic bronchitis  and emphysema.  Chronic 
bronchitis has been defined in clinical terms:  the presence of chronic 
productive cough for  at  least  3  consecutive  months  in  2  consecutive 
years.  Other  causes  of  chronic  productive  cough  must  be  ruled  out. 
Emphysema,  on  the  other  hand,  has  been  defined  by  its  pathologic 
description:  an  abnormal  enlargement  of  the  air  spaces  distal  to  the 
terminal  bronchioles  accompanied  by  destruction  of  their  walls  and 
without obvious fibrosis. The new ATS/ERS guidelines, like the GOLD 
guidelines,  have  parted  from  this  traditional  description  of  COPD, 
Similar to the changes in the definition of asthma by the NHLBI more 
than  a  decade  ago,  the  definition  of  COPD  has  undergone  major 
revision.  COPD,  like  asthma,  is  now recognized as  an  inflammatory 
disease of the airways. This is supported by extensive clinical and basic 
science research over the past 2 decades showing that asthma and COPD 
have different and distinct cellular and inflammatory mediator profiles. 
The  new  ATS/ERS  definition  reflects  these  scientific  advances: 
“Chronic obstructive pulmonary disease (COPD) is a preventable and 
treatable  disease  characterized  by  airflow limitation  that  is  not  fully 
reversible.  The  airflow  limitation  is  usually  progressive  and  is 
associated  with  an  abnormal  inflammatory  response  of  the  lungs  to 
noxious  particles  or  gases,  primarily  caused  by  cigarette  smoking. 
Although COPD affects the lungs, it also produces significant systemic 
consequences (9).
While  the  new  guidelines  do  not  specifically  include  chronic 
bronchitis and emphysema in the definition of COPD, it is made clear 
that they are considered the predominant causes of COPD. Asthma is a 
different  clinical  entity  from  COPD.  The  airflow  obstruction  is 
predominantly reversible, and the airways of asthmatics are markedly 
hyper  responsive  to  a  vast  number  of  specific  (aeroallergens)  and 
nonspecific (methacholine, histamine, cold air) inhaled substances. 
ERS (European Respiratory Society) defined COPD as “reduced 
maximum expiratory flow and slow forced emptying of lungs, which is 
slow, progressive and mostly irreversible to present medical treatment 
(16)”.
Since the GOLD definition is based on consensus between WHO 
& NHLBI which is internationally accepted,  in this study the GOLD 
criteria was used to select cases of COPD based on spirometry.
          As smokers form 90% of those with COPD, in this study COPD 
patients only with history of smoking are taken as it is easier to find 
COPD in smokers rather than in non-smokers. Since they form the bulk 
of cases in community, they represent the COPD cases in community. 
Since in this region females rarely smoke,  all  cases in this study are 
males with COPD with habit of smoking. Asthma patients have been 
excluded by reversibility of obstruction with bronchodilator (15).
SMOKING AND COPD
Smokers have higher prevalence of COPD, greater annual decline 
of  FEV1, higher  death  rates  from  COPD  compared  to  non-smokers. 
Smoking cessation is the single most effective and cost effective way to 
reduce development of COPD and stop its progression (15).
The reduction in FEV1 per year, above normal decline in adults 
for each pack year of smoking is 9 ml in males and 6 ml in females (17). 
However many people with a significant number of pack years can still 
have a normal FEV1 (17).
However smoking per se, does not cause COPD. Augesti et al in 
the journal Thorax state that, not all smokers develop COPD (18).
 In  susceptible  smokers,  there  is  an  increased  inflammatory 
response  in  lungs  whereas  in  others  there  is  only  mild  inflammation 
caused by smoking. So, some hypothesize that COPD is an autoimmune 
disease  triggered by smoking (18).  ATS -  Patient’s  section says  that 
“what determines which patients are susceptible to COPD is not known 
(19)’’. A text on airway mucus states that genetic factors may determine 
individual  susceptibility  (20).  It  has  been  calculated  that  15%  of 
smokers will  end up with symptomatic  COPD (17) and a little  more 
with asymptomatic COPD.
SMOKING
Tobacco is a global problem with 1.1 billion tobacco consumers 
in the world today. WHO estimates if current trends continue, then by 
2025, the number of smokers will increase to 1.64 billion, with most 
increase  occurring  in  developing  countries.  Four  million  people  die 
yearly from tobacco related diseases, one death in every 8 seconds. India 
is the third largest producer of tobacco in world next only to China & 
USA (10).
In India only 20% of total tobacco consumed is as cigarettes. 40% 
is consumed as bidis with the rest  as chewing tobaccos,  pan masala, 
snuff hookah, Hookli and Chumma Dhumti. It is estimated that 65% of 
all  men  use  some  form  of  tobacco  (35%  smoking,  22%  smokeless 
tobacco,  8% both).  Prevalence among women varies  widely (15% in 
Bhaunagar to 67% in AndraPradesh). However, only 3% of the women 
smoke.  Use of smokeless  tobacco by women is equal to that of men 
(10).
          The smoke from bidis contains thrice the amount of nicotine and 
carbon monoxide and 5 times as much tar as smoke from regular filtered 
cigarettes. Due to high Nicotine, bidis are more addictive than normal 
cigarettes (21).   
          Smoking can be variously defined. One definition is continuous 
use of bidis, cigarettes or any form of tobacco for more than 6 months 
(22). Non smokers are those who have never smoked (22).
Smoking was divided as per  criteria of Rastogi et al. in a study in 
IJMR as (22)
i) Mild smokers = 1-10 cigarettes or 1-15 bidis per day.
ii) Moderate  smokers  =  11-20 cigarettes  or  16-30 bidis  per 
day.
iii) Heavy smokers = > 21 cigarettes or > 31 bidis per day.
As  most  of  the  patients  who  attend  OPD  in  Government  General 
Hospital  attached  to  Madras  Medical  College  smoke  only  bidis,  for 
comparison, only patients who smoke bidis were taken as `Smokers’ in 
this study. They should have smoked for at least 6 months and all people 
labeled  as  smokers  were picked up from Rastogi’s  moderate  smoker 
class for ease for comparison.
People,  who  have  never  taken  any  tobacco  products,  smoking  or 
smokeless, were labeled as Non-smokers.
CDC definition of smokers: (23)
Life time smokers = Ever smoked even if just one puff
Current user = Smoked in last 30 days
Frequent user = Smoked 20 or more cigarettes in last 30 
days
Established user = Smoked  more  than  100  cigarettes  in 
their life time.
         All smokers in this study belong to `current users’ and `established 
users' as per CDC definition.
None of the controls used in this study had smoked even a puff.
DEPRESSION
The WHO has ranked depression as the fourth in a list of most 
urgent health problems world wide (24). Depressive disorders afflict one 
out of five women and one out of ten men at sometime during their lives 
(24).  Despite  availability  of  effective  treatments,  many  patients  with 
mood disorders are disabled and the rate of suicide is high in young and 
especially  elder  men  (24).  Although  depression  is  more  common  in 
women, more men rather than women die because of depression causing 
suicide  (24).  Nearly  half  of  all  cases  of  depression  go  undetected. 
Because  mood  disorders  underlie  50-70%  of  all  suicides,  effective 
treatment  at  national  level  should  drastically  reduce  suicides.  That 
elderly  depressed  people,  often  with medical  co-morbidity,  constitute 
the  highest  risk  group  for  suicide,  yet  escape  clinical  detection  and 
treatment is particularly problematic for public health.
Depression can be explained by various models (29) including –
1-  Aggression  turned  inward  model  of  Freud  and  Karl  Abraham 2- 
Object loss model of Freud 3- Loss of self esteem and helplessness in 
attaining goals of ego ideal model of Edwin Bribing. 4- Cognitive model 
with  thinking  on  negative  lines  model  of  Aaron  Beck  5-  Learned 
helplessness  model  of  Martin  6-  Deregulated  nor-adrenergic  and 
serotonin mediated transmission 7- Neuronal hyper excitability and 8- 
Final common pathway which place stress -diathesis interaction finally 
converging on midbrain.
In  the  study  In  Depression  in  older  people:  a  point  to 
remember in all specialties,  Acharya.A states that, `Depression is a 
common  disorder  in  older  people.  It  is  usually  undiagnosed  in  elder 
patients due to atypical symptoms, masked depressive state, mixed with 
agitation,  psychotic  delusions  and  worsening  of  physical  symptoms 
already  present  or  multiple  pains  in  extremities.  It  is  commonly 
associated co morbidity in patients of all disciplines--as in post CVA 
state  or  post  myocardial  infarction,  postoperative  state,  post 
hysterectomy or in a metabolic medical disorder like diabetes mellitus. 
Acharya.A has studied and analyzed 120 patients in different wards of 
Midnapore Medical College & Hospital and has found high incidence of 
depression and a marked improvement of symptoms after a short period 
of treatment.’(25).However Kaplan and Sadock state that, Depression is 
less common in old age compared to younger ones. A compromise is 
achieved by Hazzard Text book of Geriatric medicine whose authors 
state  that  Major  Depressive  Disorder  is  less  common in  old  age  but 
depressive symptoms are much more common in old age compared to 
younger people. (26)
The  American  Psychiatric  Association  states  that,  `Major 
depression and dysthymia may be indicated by presence of depressed 
mood,  loss of interest  or pleasure along with loss or  gain of weight, 
sleep disturbance, loss of energy, guilt, poor concentration and thoughts 
of death (27)’.
Screening for depression can be done by PRIME-MD Scale (as 
indicated by Spitzer et al in their study) (27), Beck depression inventory 
-II, Hospital Anxiety and depression scale. Zung self rating depression 
scale (29), Centre for epidemiological studies depression questionnaire 
(30) and the Geriatric Depression Scale (31)(32).
The Geriatric  depression  scale  is  widely used  and validated in 
many languages. It is a 30-item scale. Its 15 item shortened version is 
often  used  for  ease  of  administration.  Sheikh  &  Yesavage  had 
recommended use of GDS in Gerontology journal as early as in 1986 
(33) (34). This short version is considered positive if score is 5 or more 
out of 15. Ada C Mui et al in their study have found that GDS is valid 
in Indian Population (35). So, in this study, GDS-15 has been used to 
screen for depression.
SMOKING AND DEPRESSION
Scientists are still searching for a clear understanding of the link 
between depression and smoking. One explanation is ‘Self-medication 
Idea’, that Nicotine has a short term benefit effect on Neuro-transmitter 
systems involved in depression, so smoking cigarette may provide some 
relief from the feelings of depression. This effect of cigarette is short 
lasting (36). On the other hand; smoking can cause depression and make 
it worse (36). 30% of smokers show some form of depression (37).
Sad patients may turn to nicotine as a way to regulate negative 
affect. Depressive symptoms positively correlated with current smoking 
and  negatively  correlated  with  likelihood  of  quitting  smoking.  Non 
smokers are 51% less likely to be diagnosed with major depression than 
patients who had ever smoked. G.Scott Acton et al in their study found 
that  `Depression  is  much  more  common  in  contemplation  and 
preparation  stages  of  quitting  smoking  than  in  pre-contemplation  or 
maintenance stages (38)’.
Jim  Rosack  et  al in  their  study  found  `Patients  who  have 
recovered  from  major  depression  and  then  stopped  smoking  have  a 
greater likelihood of recurrence of depression on quitting tobacco (39)’.
They  explained,  Tyrosine  hydroxylase  when  increased,  lead  to 
increased nor-epinephrine, which binds to α2 receptors, whose function 
is to send signals from locus coeruleus to other parts of brain. In major 
depression,  α2 receptors  and  Tyrosine  hydroxylase  are  increased. 
Chronic  administration  of  anti-depressants  decreases  their  levels. 
Smoking also decreases levels of α2- receptors and tyrosine hydroxylase, 
thus having transient anti-depressant effect (39)’.
Janet Audrain et al in one study found that the HLA locus DRD 
2A1 is associated with smoking progression and this is potentiated by 
depressive symptoms (40).
A  common  genetic  defect  could  explain  relation  between 
depression and smoking as per Harvard Medical School (37).
Nicotine acts at Acetyl choline receptor, thus stimulating release 
of dopamine, in brain’s reward or motivation center. The brain becomes 
adapted to presence of the drug and no longer functions in absence of it. 
This will lead to depressive symptoms (37).
A study on 1000 people showed, depressed people were not more 
likely than controls to start smoking, but once started a history of daily 
smoking doubled the risk of developing major depression later on (37).
A survey of 3000 people in St. Louis area by Josepha Cheong et 
al for Psych Central found that life time prevalence of depression among 
smokers was 29% compared to 6.6% among non smokers.
Thus  it  has  been  found  that  smokers  are  more  predisposed  to 
depression. Depressed smokers are more likely to be unable to quit. So, 
use of anti-depressants  during quitting doubles the rate of  success of 
quitting.
COPD AND DEPRESSION
Burgass et al in the journal of Geriatrics state that, Depression 
occurs in 42% of patients with COPD. The lung disease may have a 
relatively  poor  long  term  outlook,  leading  to  feelings  of  frustration, 
hopelessness  and  helplessness.  Depressed  mood  lowers  energy  level 
further, making the symptoms even less tolerable (4)’.
Stage  et  al  in  Acta  Psychiatrica  Scandinavia found  that, 
Depression  in  out-patients  with COPD appears  to  be an independent 
predictor  of  mortality  (41)’.  Amongst  COPD  patients,  severe  COPD 
patients are at more risk of developing depression say Van Maren et al 
in journal Thorax(42).  In their study they found 25% depression in 
severe COPD compared to 19.6% in mild COPD and 17.6% in controls. 
Adjusting for other factors the risk of   depression in COPD was 2.5 
times that of controls.
 Depression occurs in a higher frequency in any chronic condition 
but incidence of depression is found to be much higher in COPD than 
with other major chronic conditions. “Depression is more prevalent in 
people with COPD than in people with other chronic conditions, such as 
heart  disease  and  even  cancer”  says  Dr.  Rachel  Norwood  of  the 
National  Jewish  Medical  and  Research  Center  in  Denvel  (43). 
Hypoxia  due  to  COPD  may  contribute  to  depression  (43).  Also  as 
breathing affects emotions, compromised breathing can be one reason 
for the increased prevalence of depression in COPD compared to other 
chronic conditions (43).
A  study  by  Florence  et  al  (44) showed  that  depression 
contributed to overall variance in functional status in COPD patients. 
Surprisingly  COPD  severity  and  disease  burden  did  not  contribute 
significantly to overall variance in functional status.
Among COPD patients,  Lin Mie et  al found a higher risk for 
depression among higher educated and higher income groups (45)
Kent  Roundy et  al  in  102  COPD patients  found  that  50  had 
depression or anxiety but only 18 were found out in primary care (46).
Amongst 45 COPD patients assessed by R.W.Light et al in their 
study 42% had depression (47)
`Depression was the predominant emotional disturbance in COPD 
patients’ observed A.J.McSweeny et al in their study (48).
Association  between  COPD and  depression  was  noted  in  four 
controlled studies done by L.Van Ede et al (49). 
Mark.E.Kunik  et  al  found  80%  of  patients  with  chronic 
breathing disorders suffer from depression or anxiety but only 30% were 
receiving treatment (50).
Though  there  are  many  factors  contributing  to  depression  in 
COPD, the major one is smoking.
COPD, DEPRESSION AND SMOKING
SMOKING
LEADS TO DEPRESSION 
WITH CHRONIC USE DEPRESSED SMOKERS CAN NOT QUIT SMOKING AS
NICOTINE ACTS AS 
ANTIDEPRESSENT ACUTELY
MORE DEPRESSION
COPD
REPEATED SMOKING IN 
DEPRESSED SMOKERS
A study by Edwin.J.Wagena showed that, Smoking people with 
chronic bronchitis or emphysema were more likely to report suffering 
from depressed mood when compared with smokers with no long lasting 
disease (Prevalence rate PR: 29.3 and 9.0% respectively . Odds Ratio 
(OR) for  depressed  mood  = 4.04;  95% CI = 2.56 -  0.39)  and when 
compared to smokers with a history of Heart disease, Hypertension or 
Myocardial Infarction (PR = 18.1%, OR = 1.99; 95%, CI = 1.07-3.68) or 
Rheumatoid arthritis (PR=20.1%, OR = 1.73; 95% CI = 0.96 - 3.11)’ 
(51). COPD patients thus, have higher level of depression (52), which is 
increased by smoking (53).
 Edwin.J.Wagena  et  al   in  Psychosomatic  Medicine  journal 
report a study where odds ratio for chronic bronchitis patients to have 
depression was 4.38 and the odds ratio for chronic bronchitis patients 
who smoke to have depression was 7.56(53).
          Another  study by  Edwin.J.Wagena showed that,  `  Several 
mechanisms  may  be  responsible  for  the  relation  between  smoking, 
depression  and  COPD.  The  physical  illness  itself  keeps  the  patient 
depressed.  Risk  for  depression  increases  with  increasing  severity  of 
respiratory complaints. In smokers, the risk of depression is higher due 
to negative self evaluation (54)’.
Further more as smoking is related to depression by many ways 
(including  genetic (55),  neurotransmitter  mediated  (55), shared 
environmental factors as shown in a study by Kendler et al) (56), and 
COPD being a chronic disease can itself cause depression and as COPD 
is nearly always associated with smoking, it is not surprising to find that 
COPD is much more associated with depression that most other chronic 
diseases.  So, it  becomes mandatory for all  of us to screen all  COPD 
patients for depression and treat it as it will improve their quality of life.
Second and equally important is the fact that, As the single most 
important way of affecting outcome in all stages of COPD (57) and the 
only evidence based treatment (as confirmed by Lung Health study (58)) 
for  preventing  progression  of  COPD,  quitting  smoking  is  important. 
Depression is associated with failure to quit smoking and relapse. This 
is  because  although  smoking  causes  depression  over  time,  it  has 
transient anti-depressant effect on brain and hence induces patients to 
relapse. This causes an increase in prevalence of depression by 25% in 
the first 6 months of quitting smoking. All these prevent a smoker with 
depression  from  quitting  and  thus  a  vicious  cycle  is  established. 
Smoking  causing  depression  and  depression  leading  to  smoking  and 
thus in long term smoking worsens COPD with its associated depressive 
symptoms.
Thus to break this cycle, an anti-depressant like bupropion should 
be  given  as  the  patient  quits  smoking.  This  will  prevent  relapse  of 
smoking.  This  maintenance  of  quitting  decreases  COPD  and  hence 
depression also.
Furthermore  distinguishing  depression  from  COPD  can  be 
difficult as both are associated with same emotional & physical signs 
(59) (60). So, a formal screening for depression is of help to indicate 
whether anti-depressants are of use and in this study GDS-15 is used.
Thus  COPD,  smoking  and  depression  are  inter-related  and 
breaking  this  chain  of  relation  by  using  anti-depressants  in  needed 
patients,  after  a  formal  screen,  can  provide  much  improvement  in 
quality of life of COPD patients.
Aim 
AIM OF THE STUDY
• To compare the prevalence of depression between the elderly 
smoking COPD patients, healthy elderly smokers and healthy 
elderly controls. 
• To assess the relationship between the severity of COPD and 
prevalence of depression.
Materials 
& 
Methodolog
y 
MATERIALS AND METHODS
This  study  was  conducted  in  the  Out  Patient  Clinic  of  the 
Department of Geriatric Medicine in the Government General Hospital 
attached to Madras Medical College, Chennai-03.  
Collaborating Department
Department  Of  Thoracic  Medicine  in  the  Government  General 
Hospital attached to Madras Medical College, Chennai-03. 
Study Period
     Seven months from February 2006 to August 2006.
Type of Study
      Cross Sectional study
Ethical Committe Approval
Obtained.
Study Group
Total number of subjects studied was 90.They was divided into 
three groups of 30 subjects each.
        Group A – COPD Patients who are also smokers
        Group B – Healthy Smokers 
        Group C – Normal Healthy People
GROUP A
Inclusion criteria :
1) Age > 60 yrs
2) Smoking bidis > 6 months ,  15-30 bidis/day
3) Current smokers
4) Established users
5) Takes no other tobacco product (both smokeless and 
smoking varieties)
6) FEV1 / FVC <70%. (Post-bronchodilator)
7) No other chronic disorder (Diabetes Mellitus/Ischemic 
Heart  Disease/Rheumatoid  Arthritis/ 
Seizures/Pulmonary  Tuberculosis/Bronchial  asthma  / 
Osteo Arthritis / Low Back Ache/Hypertension/other 
chronic disorders)
8) Living with Family in harmony 
9) Males
Exclusion Criteria
1) Age < 60 yrs
2) Non-smokers
3) Takes  other  smoking  (or)  smokeless  tobacco other 
than beedis
4) Females
5) Any other chronic illness
6) Any acute illness (eg) Upper Respiratory Infections 
when the patient is having the illness before clinical 
cure
7) Living alone
8) People in old age homes 
9) Post bronchodilator FEV1/ FVC > 70%.
10) CXR showing finding suggestive of tuberculosis (or) 
history of pulmonary tuberculosis.
11) Asthma ( > 12% reversibility of FEV1)
Thus Group A consists only of Smokers with COPD.
GROUP B
Inclusion criteria
1. Age > 60 yrs
2. Smoking bidis > 6 months , 15-30 bidis/day
3. Current smokers
4. Established users
5. Takes  no  other  tobacco  product  (both  smokeless  and 
smoking varieties)
6. FEV1 / FVC >70%.  (Post-bronchodilator)
7. No other chronic disorder.
8. Living with family in harmony.
9. Males
Exclusion Criteria:
1. Age < 60 yrs
2. Non-smokers
3. Takes any other smoking (or) smokeless tobacco other 
than beedis.
4. Females
5. Any other chronic illness
6. Any acute illness  (eg) URI when the patient is having 
the illness before clinical cure
7. Living alone
8. People in old age homes 
9. Post bronchodilator FEV1/ FVC < 70%. 
10.CXR showing finding suggestive of tuberculosis (or) H/
O pulmonary tuberculosis
11.Asthma associated. Reversibility of FEV1>12%.
Thus  Group  B  consists  only  of  Smokers  who  are  healthy 
otherwise.
GROUP C
Inclusion Criteria :
1. Age ≥ 60 yrs
2. Non-smokers / Not taking any form of tobacco
3. FEV1/FVC > 70%. Post bronchodilator.
4. Living with family in harmony.
5. Males
Exclusion Criteria :
1. Age < 60 yrs
2. Female
3. Any chronic illness
4. Any acute illness before clinical cure 
5. Living alone
6. Tobacco use in any form.
In all three groups, all subjects who were included were derived 
from low income house holds (<40,000 rupees per year). Every 
one  of  them  belonged  to  Occupation  category-5  (unskilled 
laborers)  .This  was  done  to  bring  about  equality  among  all 
three  groups  in  socio-economic  status  and  also  because  they 
form the majority of patients attending the OPD.
Healthy  Smokers  and  Non  Smokers  were  selected  from those 
coming for routine check up in Geriatric Medicine OPD.
Study Method
Informed consent was obtained from all subjects entering study. 
History  was  obtained  to  rule  out  any  other  chronic  and  acute 
diseases  given in  exclusion criteria.  Chest  X ray was taken to 
rule out tuberculosis and other pulmonary disorders.  ECG was 
done to rule out  primary cardiac disorders.  Blood urea,  sugar, 
creatinine  and  electrolytes  had  to  be  normal  for  subjects  to 
enter the study.
History  of  smoking  was  obtained  and  subjects  were  divided 
into two sets based on it.
Set 1 - Smokers
Set 2 - Non Smokers
Among   set-1  only  those  who  satisfy  following  criteria  were 
selected 
1. Beedis only
2. No  other  smoking  (example  –cigarette,  cigar, 
etc)/smokeless tobacco being used
3. current smokers
4. 16-30  beedis  per  day  and  so  automatically,  `established 
smokers’.
Others were excluded from set -1.
In set-2 only those who had never had even a puff of smoking 
history and having no history of using smokeless tobacco were 
included.
Spirometry was done in both sets. If there was a reversibility of 
FEV1  of  more  than  12%,  the  subjects  were  excluded.  The 
remaining subjects were stratified, as per FEV1 /FVC.
• If  FEV1 /FVC <70% in  set-1=  labeled  as  smokers  with 
COPD.(GROUP-1)
• If  FEV1  /FVC  >70%  in  set-1=  labeled  as  Healthy 
smokers. (GROUP-2)
• If  FEV1  /FVC  >70%  in  set-2=  labeled  as  Healthy 
controls. (GROUP-3)
• If FEV1 /FVC < 70% in set-2= excluded from the study.
Now  group  -  1  was  subdivided  into  four  subgroups  as  per 
GOLD criteria, using FEV1 %.
Subgroups Post bronchodilator FEV1 
%
1 > 80%
2 > 50% -  < 80%
3 > 30% - < 50%
4 < 30%
All  subjects  from  three  groups  were  administered  Geriatric 
depression scale – 15 version which has been validated in the Indian 
elderly. 
A score  of  more  than  or  equal  to  5  was  taken as  positive  for 
depression  and  a  score  of  less  than  5  was  taken  as  negative  for 
depression. 
Results were obtained and analyzed statistically. 
Methods used in analysis
1. One way ANOVA F test followed by Bonferroni t –test was 
used to compare.
a. mean ages of all three groups , 
b. FEV1/FVC of all three groups,
c. mean heights of all three groups  
d. GDS scores amongst three groups 
e. GDS scores amongst four subgroups of group 1.
2. Fischer Exact Test was used to compare GDS Results of all 
three groups
3. Chi Square test was used to compare results of GDS amongst 
four subgroups of group 1.
Results 
RESULTS
TABLE 1
AGE
GROUP
AGE
MEAN SD p value
PATIENTS 69.90 6.40 0.6671
HEALTHY SMOKERS 69.80 7.53 (N.S)
CONTROLS 68.43 7.13
Using One Way ANOVA Age has p = 0.6671 (not significant) 
Multiple Range Tests : Modified  LSD  (Bonferroni)  test  with 
significance level .05
Harmonic Mean Cell size = 30.0000
The actual range used is the listed RANGE * 1.2849 with the following 
value(s) for RANGE: 3.45
No two groups are significantly different at the .050 level
Homogeneous Subsets (highest and lowest means are not significantly 
different)
Subset 1
Group       Group 3         Group 2         Group 1
Mean         68.4333         69.8000         69.9000 
TABLE 2
HEIGHT
GROUP
HEIGHT
MEAN SD p value
PATIENTS 161.63 4.81
HEALTHY SMOKERS 162.1 4.23
CONTROLS 162.8 4.99
0.626
(N.S)
Using One Way ANOVA Height has p = 0.626 (not significant)
Multiple Range Tests : Modified LSD (Bonferroni) test with 
significance level .05
Harmonic Mean Cell size = 30.0000
The actual range used is the listed RANGE * .8556 with the following 
value(s) for RANGE: 3.45
No two groups are significantly different at the .050 level
Homogeneous Subsets (highest and lowest means are not significantly 
different)
Subset 1
Group       Group 1         Group 2         Group 3
Mean        161.6333        162.1000      162.8000
TABLE 3
RATIO OF FEV1/FVC
GROUP
FEV1/FVC
MEAN SD
p value
PATIENTS 54.3333 7.07
HEALTHY SMOKERS 75.8000 2.47
CONTROLS 78.0667 3.20
< 0.001
Using One Way ANOVA FEV1/FVC has p < 0.001 (significant)
Multiple Range Tests : Modified LSD (Bonferroni) test with 
Significance level .05
Harmonic Mean Cell size = 30.0000
The actual range used is the listed RANGE * .8584 with the following 
value(s) for RANGE: 3.45
(*) Indicates  significant  differences  which  are  shown  in  the 
lower triangle
     Mean      GROUP
    54.3333    Group 1
    75.8000    Group 2      *
    78.0667    Group 3      *
Thus Groups 2 and 3 do not differ significantly.
Homogeneous Subsets (highest and lowest means are not significantly 
different)
Subset 1
Group       Group 1
Mean       54.3333
Subset 2
Group       Group 2         Group 3
Mean       75.8000       78.0667
TABLE 4
GDS SCORES IN GROUPS
GROUP
GDS SCORES
MEAN SD
p value
PATIENTS 8.27 4.57
HEALTHY SMOKERS 5.17 3.96
CONTROLS 2.57 2.70
< 0.001
     
Using One Way ANOVA GDS Scores have p < 0.001 (significant)
Multiple Range Tests : Modified LSD (Bonferroni) test with 
significance  level .05
Harmonic Mean Cell size = 30.0000
The actual range used is the listed RANGE * .6979 with the following 
value(s) for RANGE: 3.45
(*) Indicates  significant  differences  which  are  shown  in  the 
lower triangle
Mean      GROUP
2.5667    Group 3
5.1667    Group 2      *
8.2667    Group 1      * *
Homogeneous  Subsets  (highest  and  lowest  means  are  not 
significantly different)
Subset 1
Group       Group 3
Mean        2.5667
Subset 2
Group       Group 2
Mean        5.1667
Subset 3
Group      Group 1
Mean        8.2667
TABLE 5
GDS SCORES IN SUB GROUPS
SUB GROUP
GDS SCORES
MEAN SD
p value
STAGE 1 2.50 0.71
STAGE 2 7.92 4.66
STAGE 3 8.58 4.52
STAGE 4 12.33 0.58
0.123
Using One Way ANOVA GDS SCORES have p =0.123 (not 
significant)
Multiple Range Tests : Modified LSD (Bonferroni) test with 
significance level .05
Harmonic Mean Cell size = 4.0258
The actual range used is the listed RANGE * 2.1570 with the following 
value(s) for RANGE: 4.04
(*) Indicates significant differences which are shown in the 
lower triangle.
Mean      STAGE
2.5000    Stage1
7.9231    Stage 2
8.5833    Stage 3
12.3333   Stage 4      *
Homogeneous  Subsets  (highest  and  lowest  means  are  not 
significantly different)
Subset 1
Group       Sub Group 1       Sub  Group 2        Sub Group 3
Mean          2.5000                   7.9231                  8.5833
Subset 2
Group      Sub Group 2        Sub Group 3        Sub Group 4
Mean            7.9231                   8.5833               12.3333
This  shows Sub Groups 1 and 4 differ  significantly  from each 
other but not others.
TABLE 6 
GDS RESULT IN GROUPS
GDS RESULT POSITIVE NEGATIVE PERCENTAGE OF POSITIVES
PATIENTS         19        11 63.3
SMOKERS 9 21 30
CONTROLS 2 28 6.7
DEPRESSION AMONGST THREE 
GROUPS
6.7
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TABLE 7a    GDS RESULT IN GROUPS
COPD PATIENTS AND HEALTHY CONTROLS - 
GROUP DEPRESSED NOT DEPRESSED p VALUE
COPD     19       11
CONTROL
S
      2       28
p <0.001
Fischer’s Exact Test used. p <0.001(very significant)
TABLE 7b
COPD PATIENTS AND HEALTHY SMOKERS
GROUP DEPRESSED NOT DEPRESSED p VALUE
COPD 19 11
HEALTHY 
SMOKERS
9 21 0.0191
Fischer’s Exact Test used. p = 0.0191 (significant)
TABLE 7c
HEALTHY SMOKERS AND CONTROLS
GROUP DEPRESSED NOT DEPRESSED p VALUE
HEALTHY 
SMOKERS
9 21
CONTROLS       2 28
0.0419
Fischer’s Exact Test used. p = 0.0419 (significant)
TABLE 8 
GDS RESULTS IN SUB GROUPS
GDS RESULT STAGE 1
STAGE 
2
STAGE 
3
STAGE 
4
p value
POSITIVE 0 8 8 3
NEGATIVE 2 5 4 0
0.15327
 Chi-Square                  Value           DF               Significance
 Pearson                          5.2664        3                     0.15327
Using Chi-Square test p = 0.15327 (not significant).
TABLE 9 
GDS RESULTS IN SUB GROUPS
GDS 
RESULT
POSITIVE NEGATIVE
PERCENTAGE OF 
POSITIVES
STAGE 1 0 2 0
STAGE 2 8 5 61.5
STAGE 3 8 4            66.7
STAGE 4 3 0 100
DEPRESSION AMONG SUBGROUPS
0
61.5 66.7
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150
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Discussion 
DISCUSSION
This study was done to find out the association between COPD, 
depression  and  smoking  in  elderly  people.  Here  90  subjects  were 
divided into three groups of 30 each. 
Group 1 - COPD patients who are also smokers.
Group 2 - Healthy smokers.
Group 3 - Healthy controls
Group 1 was subdivided into four sub groups. 
Sub group 1 - FEV1 > 80%
Sub group 2 - FEV1 > 50% to <80%
Sub group 3 - FEV1 > 30% to <50%
Sub group 4 - FEV1 < 30%
In all these volunteers, Spirometry and Geriatric Depression Scale 
were administered, along with an enquiry about their smoking patterns. 
Statistical analysis was done and results were compared.
AGE
Age  affects  depression  and  so,  comparison  between  groups  of 
different Ages will bias the study.
To eliminate bias, age was compared in all three groups using one 
way ANOVA followed by Modified LSD (Bonferroni) test. p value of 
0.6671 was obtained. This is not significant. So, `Age’ as a confounding 
factor was ruled out. 
HEIGHT
       Using one way ANOVA, followed by Modified LSD (Bonferroni) 
test,  Height  was compared in all  three groups.  p value of 0.626 was 
obtained. This is not significant. So, `Height’ as a confounding factor 
was ruled out.
FEV1/FVC
FEV1/FVC was used to separate Group 1 from other two groups. 
FEV1/FVC < 70% indicates COPD and this is internationally accepted 
definition (15). So, it was just enough to prove that FEV1/FVC does not 
vary between Groups 2 and 3. By use of Modified LSD (Bonferroni) test 
it  was  found  that  the  means  of  Groups  2  (75.8000)  and  Group  3 
(78.0667) do not differ significantly. Thus the role of FEV1/FVC as a 
confounding factor in non-COPD groups was ruled out.
GDS SCORES
         GDS scores were given to an individual person based on fifteen 
questions. A person can have any score between zero to fifteen.
GDS scores were compared between all three groups using one 
way ANOVA, followed by Modified LSD (Bonferroni) test. Significant 
difference  was found between all  three groups (p < 0.001) and each 
group differed from each other significantly.
GDS  scores  were  compared  between  all  four  sub-groups  of 
Group-1  using  one  way  ANOVA,  followed  by  Modified  LSD 
(Bonferroni) test. Significant difference was not found between all four 
sub-groups (p  = 0.123). However two homogenous sub sects occurred 
(sub-groups  1,2,3  and  sub-groups  2,3,4).This  shows  that  sub-group1 
varied from sub-group 4 but other  sub- groups did not differ from each 
other significantly.
GDS RESULTS
Though  GDS  scores  were  compared,  comparison  of  results 
(positive or negative) is much more important.
          Geriatric Depression Scale was specifically developed to find out 
depression in elderly, as depression in elderly manifests differently from 
that of younger age group. Elderly have more somatic complaints due to 
depression  compared  to  young  patients.  The  original  version  of 
Geriatric  Depression  Scale  consists  of  30  parameters  .Here  Normal 
score is 5 (plus or minus 4). Patients with mild depression have a score 
of 15 (plus or minus 6) and patients with severe depression have a score 
of 23 (plus or minus 5). . Ada C Mui et al in their study have found that 
GDS is valid in Indian Population (35).
          A Shorter Version, Geriatric Depression Scale – 15, is often used 
for ease of administration. Sheikh & Yesavage had recommended use of 
GDS in Gerontology journal as early as in 1986 (33). This short version 
is considered positive if score is 5 or more out of 15. This short version 
is  recommended  in  Current  Geriatric  Diagnosis  and  Treatment  2004 
edition.  Thus  as  per  this  there can be only two results  – Positive or 
Negative.
GDS SCORE DEPRESSION
0 - 4 Positive
5 - 15 Negative
This shorter version of GDS was used in this study.
In this study prevalence of depression 
• Among smoking COPD patients was 63.3%.
• Among healthy smokers was 30% and 
• Among healthy controls was 6.7%.
In the current study, it has been found that the prevalence of depression 
•  Between  elderly  COPD  patients  who  smoke  and  healthy 
elderly  non  smokers  was  highly  statistically  significant  (p 
<0.001). 
• Between the elderly COPD patients who smoke and healthy 
elderly smokers (p = 0.0191) was statistically significant.
• Between  healthy  elderly  smokers  and  healthy  elderly  non 
smokers (p = 0.0419) was also statistically significant. 
This  is  a  very valid observation considering the fact  that  most 
COPD patients in the community are not screened for depression and 
also due to the fact  that  depression more than adds to the morbidity 
caused by COPD.
This study also observes that the disease `COPD’ per se can cause 
depression as indicated by an increased prevalence of depression among 
smoking COPD patients compared to healthy smokers.
This  study also points out that  smoking is associated with one 
more problem that is rarely addressed to – that is, Smokers are more 
likely to be depressed. This assumes significance considering the fact 
that depressed smokers are less likely to quit smoking, compared to non 
depressed  ones.  Since  quitting  smoking  reduces  lots  and  lots  of 
morbidity  and  mortality,  it  becomes  a  necessity  for  the  Medical 
Community  to  come  up with  ways  that  will  increase  the  success  of 
quitting.  Since  `depression’  prevents  quitting,  a  formal  screen  for 
depression and treatment with antidepressants will enhance the success 
of quitting. This view is supported by the recommendation of the anti-
depressant  bupropion  for  quitting  by  FDA  and  its  success  in  this 
situation.
The results thus show that COPD per se can cause depression and 
when smoking adds to it, the prevalence is much higher than in healthy 
non  smokers.  Since  most  COPD  patients  are  smokers,  the  above 
observation goes on to stress that – Screening for Depression is a sin qua 
non in all COPD patients.  
          In this study prevalence of depression among subgroups of 
smoking COPD patients were 0% in stage 1 COPD, 61.5% in stage 2 
COPD,  66.7% in  stage  3  COPD and  100% in  stage  4  COPD.  GDS 
results were compared applying Chi-Square test  and was found to be 
insignificant (p =0.15377) amongst all four sub-groups. Even though the 
comparison  between  the  stages  of  COPD and  GDS results  were  not 
statistically significant, it has been found that the severe COPD patients 
had more prevalence of depression compared to milder groups.
HEALTHY SMOKERS AND CONTROLS 
Thus this study observed a significant increase in the prevalence 
of depression amongst healthy smokers compared to healthy controls. 
This finding correlates with a survey reported in Psychcentral of 3,000 
individuals in the St. Louis area which confirmed that lifetime frequency 
of  major  depression  was  more  common  among  smokers  than 
nonsmokers (6.6 vs. 2.9 percent).
          This also correlates with the findings of a study reported by 
Harvard  Medical  School  on  1000  people  which  showed  depressed 
people  were not  more  likely  than controls  to  start  smoking but  once 
started,  a history of daily smoking doubled the risk of developing major 
depression later on (37).
This  also  correlates  with  the  findings  of  a  study  reported  by 
Stephen J.  Jay  MD  among persons  65  years  of  age  or  older;  the 
smoking rate in that study was reported as 12.9% among women and 
21.2% among men. Smoking was a major  risk factor for 7 of the 14 
leading causes of death among persons 60 years of age and older and 
was a complicating factor for 3 others in that study. Thirty percent to 
50% of smokers had a history of depression.  Thus, that study concluded 
that, `smoking is not uncommon in the elderly and is associated with 
both depression and numerous adverse health effects, including illness, 
death, reduced  health  care  utilization,  reduced  physical  activity, and 
altered  metabolism  of  medications  (61)’The  Present  study  correlates 
closely with this above mentioned study with a depression rate among 
smokers coming to 30%.
HEALTHY SMOKERS AND COPD PATIENTS WHO SMOKE
COPD
SMOKING DEPRESSION
As  already  mentioned,  this  study  also  observed  a  significant 
increase  in  the  prevalence  of  depression  among  COPD patients  who 
smoke compared to healthy smokers. 
          This correlates with the study by Edwin.J.Wagena (51) which 
showed  that,  Smoking  people  with chronic  bronchitis  or  emphysema 
were  more  likely  to  report  suffering  from  depressed  mood  when 
compared with smokers with no long lasting disease (Prevalence rate 
PR: 29.3 and 9.0% respectively. Odds Ratio, OR for depressed mood = 
4.04; 95% CI = 2.56 - 0.39). 
          This also correlates with the findings of another study reported by 
Edwin.J.Wagena et al  in Psychosomatic Medicine journal   where 
odds ratio for chronic bronchitis patients to have depression was 4.38 
and the odds ratio for chronic bronchitis patients who smoke to have 
depression was 7.56(53).
COPD PATIENTS WHO SMOKE AND HEALTHY CONTROLS
As already mentioned, this study also observed a very significant 
difference in the prevalence of depression among COPD patients who 
smoke compared to healthy non-smoking controls.
          This is in correlation with studies of  L.Van Ede et al (49 )who 
found  an  increase  in  depression  among  COPD patients  compared  to 
controls in three of his studies. Two other studies by of  L.Van Ede et al 
(49)  which  did  not  show  a  significant  difference  in  prevalence  of 
depression between COPD patients and controls were excluded by the 
Author  himself  as  he  found  that  those  studies  had  defective 
methodology.  He then showed an increased prevalence of  depression 
COPD  patients  in  general  population  in  three  of  six  non  controlled 
studies.
This  is  also  in  correlation  with  the  study  of  ABEBW 
M.YOHANNES  (62)who  compared  the  prevalence  of  depressive 
symptomatology in elderly outpatients with stable COPD with that in 
healthy controls  and age-matched patients  with other  disabilities, and 
also assessed the relation between degree of disability, quality of life and 
depressive symptoms.  The subjects were 96 older people with COPD 
[56 men; aged 70–93 (mean 78) years], 55 normal controls [23 men; 
aged 70–90 (mean 78) years] and 53 disabled controls [27 men; aged 
70–92  (mean  78) years].  Exclusion  criteria  were  acute  respiratory 
exacerbation or use of oral steroids in the last 6 weeks, known previous 
psychiatric disorder and acute or chronic confusion.  The study found 
that depressive symptoms are common in elderly patients with COPD; 
prevalence and/or severity of depressive symptoms may be greater in 
those  who are  most  disabled.  In  this  study  also  similar  results  were 
obtained  with  increase  in  prevalence  of  depression  among  COPD 
patients with a much higher prevalence in Stage 4 disease.
This  study also is  in correlation with a study reported by  A J 
McSweeny et al in Archieves of Internal Medicine (48).In that study 
203 patients with COPD and 73 controls were selected. Depression was 
the predominant emotional disturbance noted in COPD patients.
          According to a recent survey by Mark Kunic and others, anxiety 
and depressive  disorders  were found in  60  to  80  percent  of  military 
veterans  with  COPD.  Incidence  of  smoking  and  mood  disorders  is 
significantly  higher  in  VA clinic  patients (50).Thus  the present  study 
correlates with the study of Mark Kunic et al in that in this study also 
the prevalence of depression is 63%
          This incidence of depression among COPD patients in this study 
is however higher than the study by Kent Roundy et al (In 102 COPD 
patients  found  that  50  had  depression  or  anxiety)  (46).  This  is  also 
higher than the study by  R.W.Light et al who used Beck Depression 
Inventory in 45 patients and found 42% of them had depression (47). 
This may be due to the fact that all patients who entered this study were 
of  lower  socio-economic  status  and  this  could  have  increased  the 
prevalence of depression equally in all three groups. 
DEPRESSION AMONG DIFFERENT STAGES OF COPD - 
This study observed an increase in the prevalence of depression 
among COPD patients of Stage 4 compared to Stage 1. The prevalence 
of  depression  increases  from 0% in Stage  1 to  61.5% in  Stage  2  to 
66.7% in Stage 3 and becomes 100% in Stage 4. Though there is an 
increase in the prevalence of depression with increasing stage of COPD, 
statistically significant increase between all stages is not found.  This 
contrasts with a study by Van Manen et al in journal Thorax (42). In 
their study they found 25% depression in severe COPD compared to 
19.6% in mild COPD and 17.6% in controls. This difference between 
the two studies might have been due to the smaller sample size used in 
this study. However this study correlates with the study of Van Manen 
et al in that prevalence of depression increases with increasing severity 
in both studies.
LIMITATIONS OF THIS STUDY 
In this study COPD patients without a history of smoking were 
not included due to the difficulty in getting such patients. Only a few of 
them came to Out Patient Department (as they constitute only a minority 
of  COPD  patients)  and  nearly  every  one  of  them  had  other 
predispositions for depression and so could not enter the study. Had this 
study included them, this study would have been of more value. Still, as 
most  COPD  patients  in  the  community  are  smokers,  this  study 
represents  the  bulk  of  COPD  patients  in  the  community  and  their 
predisposition for depression.
         The stages of COPD were not equally represented in this study. 
Most patients were of Stage 2 or 3. This may be due to the fact that most 
if not all patients of Stage 1 have no symptoms and so rarely come to 
OPD for treatment. Most patients in Stage 4 may be disabled secondary 
to  their  lung  disease  and  many  of  them  may  be  bed  ridden,  either 
admitted in ward or being treated at home itself and so they also form 
only a small percentage of out patients. These problems of this study 
could  have  been  solved,  had  the  study  been  carried  out  in  the 
community rather than in the hospital.
          Future studies are needed to find out how many COPD patients 
with  depression  are  really  being  treated  for  their  depression.  Also 
studies  are  needed  to  prove  that  antidepressants  really  help  COPD 
patients and improve their morbidity and mortality.
Summary 
SUMMARY
This study was done to find out the correlation between COPD, 
Smoking and Depression. Three Groups of subjects were selected with 
30 subjects in each Group. Group 1 consisted of COPD patients with 
every  one  of  them  being  smokers.  Group  2  consisted  of  healthy 
smokers.  Group  3  consisted  of  healthy  controls.  Group  1  was  sub 
divided  into  four  sub  groups  based  on  the  severity  of  COPD 
(FEV1%).All FEV1 values were post bronchodilator values (63).
          All  subjects  were  administered  Spirometry  and  Geriatric 
Depression Scale – 15 version along with a detailed history of smoking.
          Results obtained were subjected to statistical analysis. It was 
found that COPD patients who smoke were more depressed than healthy 
smokers, who in turn were more depressed than healthy controls. This 
study also observed an increase in the percentage of depressed patients 
with increasing severity of COPD, though that increase did not reach 
statistical significance.
Thus this study observes a very high prevalence of depression in 
COPD patients  who smoke compared to healthy controls.  This  study 
concludes that, all COPD patients should be screened for depression.
Conclusion 
CONCLUSION
The prevalence  of  depression  was  evaluated  in  COPD patients 
and healthy smokers. This study shows
 Elderly  COPD  patients  who  also  smoke  have  a  very  high 
prevalence  of  depression  compared  to  healthy  elderly  non 
smokers.
 Elderly  smokers  with  COPD  have  higher  prevalence  of 
depression compared to elderly healthy smokers.
 Elderly healthy smokers have higher prevalence of depression 
than healthy elderly non smokers.
 Prevalence  of  depression  increases  with  increasing  stage  of 
COPD but not to a significant extent.
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O.P. 
No. AGE HEIGHT
FEV1
PREDICTED
FVC
PREDICTED
FEV1
OBSERVED
FVC
OBSERVED
FEV1/ 
FVC
GDS
SCORE RESULT
P1 Vadivel 417/06 65 155 1.99 2.52 1.59 2.33 68 2 N
P2 Manickam 1132/05 63 160 2.23 2.82 1.69 2.64 64 2 N
P3 Devandran 608/06 67 167 2.32 2.98 1.86 2.81 66 3 N
P4 Kathirvel 654/04 70 160 2.05 2.66 1.39 2.44 57 3 N
P5 Babu 280/03 72 165 2.19 2.86 1.23 1.98 62 12 P
P6 RajaPillai 42/04 75 165 2.11 2.80 1.31 2.30 57 11 P
P7 Gopalan 1034/03 80 165 1.99 2.68 1.09 2.22 49 12 P
P8 Venkatesan 689/04 60 160 2.31 2.88 1.20 2.07 58 3 N
P9 Annamalai 766/06 66 172 2.60 3.35 1.95 3.25 60 11 P
P10 Chellan 123/04 67 163 2.24 2.88 1.19 2.48 48 12 P
P11 Thomas 423/05 68 167 2.37 3.05 1.21 2.50 49 3 N
P12 Seeman 1320/05 67 160 2.13 2.73 1.41 2.71 52 9 P
P13 Boobalan 78/04 69 164 2.23 2.88 1.43 2.65 54 11 P
P14 Shanmugam 321/02 71 157 1.92 2.49 1.29 2.35 55 1 N
P15 Kali 987/04 74 170 2.33 3.07 1.28 2.78 46 13 P
P16 Danasekaran 543/03 61 156 2.13 2.66 1.00 1.85 54 12 P
P17 Siva 241/05 77 153 1.69 2.25 0.64 1.56 41 11 P
P18 Sunderasan 432/04 74 160 1.95 2.57 0.72 1.80 40 2 N
P19 Antony 564/02 79 163 1.94 2.61 0.68 1.26 54 10 P
P20 Prakasam 865/05 77 158 1.80 2.40 0.77 1.33 58 4 N
P21 Baskaran 786/03 77 164 2.03 2.70 0.81 1.35 60 12 P
P22 Iyyappan 510/04 78 159 1.81 2.43 0.56 0.97 58 II P
P23 AllaPitchai 126/01 78 167 2.11 2.83 0.57 1.10 52 12 P
P24 ThambiRaj 43/03 61 164 2.43 3.06 0.70 1.48 47 13 P
P25 Palaniappan 622/05 61 154 2.09 2.61 0.59 1.11 53 12 P
P26 Munusamy 765/02 68 161 2.14 2.75 0.73 1.18 62 3 N
P27 Seenivasan 564/04 72 162 2.08 2.71 0.79 1.80 44 15 P
P28 MahaRajan 542/01 63 165 2.42 3.07 1.04 2.17 48 10 P
P29 Kannappan 894/05 77 153 1.69 2.25 0.83 1.54 54 2 N
P30 Sahul 542/06 60 160 2.31 2.88 0.95 1.58 60 11 P
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S1 Radhakrishnan 330/06 60 170 2.68 3.39 2.14 2.93 73 2 N
S2 Gangadaran 234/06 63 165 2.42 3.07 2.08 2.77 75 0 N
S3 Munusamy 143/06 79 157 1.71 2.30 1.45 1.89 77 3 N
S4 Subramoni 220/06 65 160 2.18 2.77 1.81 2.42 75 4 N
S5 Kuppusamy 562/06 74 164 2.10 2.77 1.81 2.18 83 10 P
S6 Alagesan 321/06 60 156 2.16 2.68 1.81 2.39 76 4 N
S7 Govindan 663/06 71 163 2.14 2.79 1.84 2.45 75 4 N
S8 Mani 231/06 78 162 1.93 2.58 1.74 2.26 77 11 P
S9 Ramasamy 169/06 77 158 1.80 2.40 1.49 1.89 79 1 N
S10 Perumal 612/06 68 161 2.14 2.75 1.73 2.34 74 4 N
S11 Damodaran 320/06 63 160 2.23 2.82 2.05 2.74 75 11 P
S12 Abdul 280/06 60 160 2.31 2.88 1.94 2.66 73 2 N
S13 Arumugam 345/06 79 169 2.16 2.91 1.88 2.51 75 9 P
S14 Kannan 730/06 61 154 2.09 2.61 1.76 2.37 74 2 N
S15 Murugesan 432/06 78 159 1.81 2.43 1.54 2.08 74 11 P
S16 Chellappan 881/06 78 167 2.11 2.83 1.79 2.46 73 11 P
S17 Ponnusamy 465/06 60 156 2.16 2.68 1.86 2.41 77 4 N
S18 Samy 423/06 78 167 2.11 2.83 1.77 2.36 75 14 P
S19 Ragavan 876/06 79 160 1.83 2.46 1.46 1.98 74 3 N
S20 Sami 795/06 67 160 2.13 2.73 1.83 2.51 73 2 N
S21 Madavaraj 154/06 72 162 2.08 2.71 1.75 2.24 78 3 N
S22 Mohd.Bazir 397/06 79 160 1.83 2.46 1.54 1.92 80 2 N
S23 Jayaraman 112/06 79 169 2.16 2.91 1.90 2.38 80 3 N
S24 Ganasan 203/06 63 163 2.34 2.97 1.99 2.69 74 12 P
S25 Duraisamy 814/06 67 160 2.13 2.73 1.79 2.35 76 2 N
S26 Saminathan 734/06 60 170 2.68 3.39 2.41 3.30 73 8 P
S27 Farook 510/06 67 160 2.13 2.73 1.83 2.32 79 4 N
S28 Sambasivam 208/06 77 164 2.03 2.70 1.68 2.22 76 3 N
S29 Palani 176/06 61 164 2.43 3.06 2.11 2.82 75 2 N
S30 Krishnan 312/06 71 163 2.14 2.79 1.75 2.31 76 4 N
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FEV1
OBSERVED
FVC
OBSERVED
FEV1/ 
FVC
GDS
SCORE RESULT
C1 Dilli 215/06 60 165 2.52 3.16 2.42 3.14 77 1 N
C2 Gopalan 532/06 78 165 2.04 2.73 1.94 2.55 76 10 P
C3 Muniandi 419/06 63 170 2.60 3.32 2.34 3.12 75 0 N
C4 Manikannan 365/06 65 165 2.32 3.02 2.30 2.77 83 2 N
C5 Ammavasai 254/06 73 159 1.94 2.54 1.82 2.28 80 3 N
C6 Elumalai 450/06 67 158 2.05 2.63 1.97 2.43 81 2 N
C7 Arunachalam 621/06 71 170 2.40 3.14 2.14 2.67 80 4 N
C8 Govindasamy 524/06 77 170 2.25 3.00 2.27 2.91 78 2 N
C9 Chandrasekaran 709/06 60 156 2.16 2.68 1.99 2.42 82 3 N
C10 Raj 604/06 78 167 2.11 2.83 1.92 2.46 78 2 N
C11 Mohan 274/06 71 163 2.14 2.79 2.03 2.68 76 4 N
C12 Nadaraj 711/06 79 160 1.83 2.46 1.65 2.06 80 13 P
C13 Muthukrishnan 479/06 65 160 2.18 2.77 1.98 2.54 78 1 N
C14 Christopher 583/06 61 156 2.13 2.66 2.00 2.36 85 2 N
C15 Hari 716/06 79 169 2.16 2.91 2.18 2.95 74 3 N
C16 Rangiah 178/06 60 165 2.52 3.16 2.29 3.14 73 2 N
C17 Vaelu 771/06 67 158 2.05 2.63 1.93 2.57 75 1 N
C18 Arjunan 498/06 77 170 2.25 3.00 2.12 2.75 77 3 N
C19 Srinivasan 698/06 65 165 2.32 3.02 2.13 2.70 79 2 N
C20 Varadan 297/06 67 160 2.13 2.73 2.04 2.49 82 1 N
C21 Chari 680/06 60 170 2.68 3.39 2.55 3.44 74 2 N
C22 Keasavan 371/06 60 160 2.31 2.88 2.24 2.87 78 0 N
C23 Mohd.Ali 727/06 67 160 2.13 2.73 1.98 2.61 76 4 N
C24 Sankar 596/06 71 163 2.14 2.79 1.93 2.38 81 3 N
C25 Baasha 654/06 61 156 2.13 2.66 1.96 2.33 84 1 N
C26 Vasudevan 387/06 77 153 1.69 2.25 1.52 1.98 77 1 N
C27 Chitiah 744/06 79 157 1.71 2.30 1.62 2.23 73 2 N
C28 SultanMohd. 190/06 74 164 2.10 2.77 1.83 2.44 75 1 N
C29 Ethiraj 820/06 61 164 2.43 3.06 2.21 2.84 78 2 N
C30 Dharman 823/06 60 166 2.61 3.25 2.48 3.22 77 0 N
Annexure 
II 
PROFORMA
Name –                                                                   Age - 
Sex –                                                                      Height - 
Address –                                                                O.P.Number-
Short History of Present Illness -                            Care Giver Support - 
Smoking History –
Co-morbid Illness – 
Geriatric Depression Scale score – 
FEV1 Predicted -                                                     FEV1 Reversibility– 
Post Bronchodilator FVC Observed –                     FVC Predicted -
Post Bronchodilator FEV1 Observed – 
FEV1/FVC –                                                              FEV1% - 
GROUP – Smoking COPD patients/ Healthy smokers/Controls
Sub Group (if COPD patient) – 
Geriatric Depression Scale Result – Positive / Negative
GERIATRIC DEPRESSION SCALE(GDS) SHORT FORM
HOW YOU FELT THIS PAST WEEK
Are you basically satisfied with your life? yes NO
Have you dropped many of your activities and interests? YES no
Do you feel that your life is empty? YES no
Do you often get bored? YES no
Are you in good spirits most of the time? yes NO
Are you afraid that something bad is going to happen to 
you?
YES no
Do you feel happy most of the time? yes NO
Do you often feel helpless? YES no
Do you prefer to stay at home, rather than going out and 
doing new things?
YES no
Do you feel you have more problems with memory than 
most?
YES no
Do you think it is wonderful to be alive now? yes NO
Do you feel pretty worthless the way you are now? YES no
Do you feel full of energy? yes NO
Do you feel that your situation is hopeless? YES no
Do you think that most people are better off than you 
are?
YES no
Score: _____ (Number of "depressed" answers - ones that are bold)
Answers in bold indicate depression. 
ABBREVIATIONS
1. COPD – Chronic Obstructive Pulmonary Disease
2. GOLD – Global  Initiative  Of  Obstructive  Lung 
Diseases
3. ATS – American Thoracic Society
4. GDS – Geriatric Depression Scale
5. ERS – European Respiratory Society
6. FEV1 – Forced Expiratory Volume In One Second
7. FVC – Forced Vital Capacity
8. DALYs – Disability Adjusted Life Years
9. WHO – World Health Organization
10.NHLBI – National Heart, Lung And Blood Institute
11. CDC – Center For Disease Control
12.IJMR – Indian Journal Of Medical Research
13.CVA – Cerebro Vascular Accident
14.PR – Prevalence Rate
15.OR – Odds Ratio
16.CI – Confidential Interval
17.OPD – Out Patient Department
18.CxR – Chest X-Ray 
19. URI – Upper Respiratory Tract Infection
